Supplementary Methods 1 Instruments. The particle size and Zeta potential were measured by the Zetasizer (Nano ZS, Malvern). 2
The fluorescence intensity was measured by a microplate reader (Infinite M200 PRO, Tecan). 
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Synthesis and characterization of m-HA. Sodium hyaluronate (HA, 1.08g, 3 mg/mL) was dissolved in 20 45 mL of DI water. HS-PEG-NH 2 was dissolved in 45 mL of DI water. Solutions were combined, EDC 21 and NHS were added as powder, and system pH was adjusted to 5.5 ± 0.3 with NaOH/HCl solutions. 22
After 45 min, reaction pH was increased to and maintained at 7.3 ± 0.3. The reaction was allowed to 23 proceed at room temperature for 4 days. After dialysis against DI water for 48 h, the white powder (m-HA) 24 was obtained by means of freeze-drying, and characterized by were functionalized with MUA via ligand exchange reaction. The resulting MUA functionalized gold 2 nanoparticles were then dispersed in DMF, followed by the addition of CD in presence of DCC and 3 DMAP. The reaction was allowed overnight. After the synthesis, the CD functionalized gold nanoparticles 4 (GNPs) were isolated through centrifugation, washed with DI water and filtered using PVDF 45-μm filter 5 (Fisherbrand) to remove excess DCC. For loading of Dox, 1 mL of GNP was incubated with 100 μL of 6 triethanolamine (TEA)-treated Dox in dimethyl sulfoxide (DMSO) (5 mg mL -1 ) with stirring at room 7 temperature overnight. The resulting Dox-loaded GNP/Dox was extensively washed with PBS via 8 centrifugation to remove the excess Dox. The surface functionalization degree was fine tuned to achieve 9 the same LC as LM-NP/Dox-L (24%). thoroughly washed and lysed. After centrifugation, the metal ion concentrations and total protein amounts 24 in supernatants were determined by ICP-MS and BCA assay, respectively. The pellets were carefully 25 washed with DI water and collected for TEM imaging and element analysis. 26 27 Determination of maximum tolerated dose. The maximum tolerated dose (MTD) was defined as the 28 highest dose that does not cause major adverse reactions in mice over 10 days post single dose intravenous 29 injection 6 . In this study, major adverse reactions were considered to be immediate death, impaired 30 mobility or irregular breathing that could not be recovered within a day, over 10% weight loss over 31 continuous days, or histological evidence of organ toxicity. 32
